

## 8 Literaturverzeichnis

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. *N Engl J Med.* 1999;341:1368-1378.
2. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. *Ann Surg.* 1996;224:463-473.
3. Farley DR, Weaver AL, Nagorney DM. "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. *Mayo Clin Proc.* 1995;70:425-429.
4. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. *Clin Liver Dis.* 2001;5:191-218.
5. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. *Oncogene.* 2000;19:6122-6129.
6. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. *N Engl J Med.* 1995;333:1757-1763.
7. Folkman J. New perspectives in clinical oncology from angiogenesis research. *Eur J Cancer.* 1996;32A:2534-2539.
8. Kerbel RS. Tumor angiogenesis: past, present and the near future. *Carcinogenesis.* 2000;21:505-515.
9. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. *Nature.* 2000;407:249-257.
10. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. *Int J Dev Biol.* 1998;42:995-1002.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell.* 2000;100:57-70.
12. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell.* 1996;86:353-364.
13. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. *Eur J Cancer.* 1996;32A:2386-2393.
14. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. *Curr Top Microbiol Immunol.* 1999;237:1-30.
15. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J.* 1999;13:9-22.
16. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. *Semin Cancer Biol.* 1999;9:211-220.

17. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol Endocrinol*. 1991;5:1806-1814.
18. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *J Biol Chem*. 1991;266:11947-11954.
19. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. *Mol Biol Cell*. 1993;4:121-133.
20. Finkenzeller G, Marme D, Weich HA, Hug H. Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. *Cancer Res*. 1992;52:4821-4823.
21. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. *J Biol Chem*. 1994;269:6271-6274.
22. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. *Proc Natl Acad Sci U S A*. 1998;95:3609-3614.
23. Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis. *Breast Cancer Res Treat*. 1995;36:139-155.
24. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. *J Biol Chem*. 1995;270:19761-19766.
25. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, Folkman J, D'Amore PA. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. *Mol Med*. 1995;1:182-193.
26. Steinbrech DS, Mehrara BJ, Saadeh PB, Greenwald JA, Spector JA, Gittes GK, Longaker MT. VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. *Am J Physiol Cell Physiol*. 2000;278:C853-C860.
27. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B, Rosewicz S. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. *Gut*. 2001;48:87-96.
28. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. *Breast Cancer Res Treat*. 1995;36:127-137.

29. Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinate fashion To recruit and expand tumor vasculature. *Mol Cell Biol.* 2000;20:7282-7291.
30. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. *J Cell Biol.* 1995;129:895-898.
31. Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. *Cancer Res.* 1996;56:1615-1620.
32. Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marme D, Martiny-Baron G. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. *Cancer Res.* 1999;59:3185-3191.
33. Vitaliti A, Wittmer M, Steiner R, Wyder L, Neri D, Klemenz R. Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. *Cancer Res.* 2000;60:4311-4314.
34. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. *Cancer Res.* 2000;60:5117-5124.
35. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. *Nature.* 1993;362:841-844.
36. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. *Nat Med.* 1999;5:1359-1364.
37. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, Hayashi K, Mosher DF, Sugimachi K, Tsuneyoshi M, Kuwano M. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. *Hepatology.* 1998;28:1512-1517.
38. Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, Nagashima K, Katoh H. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. *Anticancer Res.* 1999;19:2257-2260.
39. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell.* 2000;103:295-309.
40. Blobel GA, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. *N Engl J Med.* 2000;342:1350-1358.
41. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. *Cell.* 1998;93:1159-1170.

42. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. *J Cell Biol.* 1990;110:1361-1367.
43. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. *Cell.* 1998;95:737-740.
44. Attisano L, Wrana JL. Smads as transcriptional co-modulators. *Curr Opin Cell Biol.* 2000;12:235-243.
45. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. *FASEB J.* 1999;13:2105-2124.
46. Massague J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. *EMBO J.* 2000;19:1745-1754.
47. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. *Cancer Res.* 1998;58:5329-5332.
48. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. *Cancer Res.* 1999;59:320-324.
49. Yokomuro S, Tsuji H, Lunz JG, III, Sakamoto T, Ezure T, Murase N, Demetris AJ. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. *Hepatology.* 2000;32:26-35.
50. Gold LI. The role for transforming growth factor-beta (TGF-beta) in human cancer. *Crit Rev Oncog.* 1999;10:303-360.
51. DeCoteau JF, Knaus PI, Yankelev H, Reis MD, Lowsky R, Lodish HF, Kadin ME. Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. *Proc Natl Acad Sci U S A.* 1997;94:5877-5881.
52. Dolecki GJ, Connolly DT. Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. *Biochem Biophys Res Commun.* 1991;180:572-578.
53. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. *Cancer Lett.* 1996;102:209-215.
54. Chua CC, Hamdy RC, Chua BH. Mechanism of transforming growth factor-beta1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells. *Biochim Biophys Acta.* 2000;1497:69-76.

55. Saadeh PB, Mehrara BJ, Steinbrech DS, Dudziak ME, Greenwald JA, Luchs JS, Spector JA, Ueno H, Gittes GK, Longaker MT. Transforming growth factor-beta1 modulates the expression of vascular endothelial growth factor by osteoblasts. *Am J Physiol.* 1999;277:C628-C637.
56. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. *J Biol Chem.* 1995;270:12607-12613.
57. Finkenzeller G, Sparacio A, Technau A, Marme D, Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. *Oncogene.* 1997;15:669-676.
58. Schafer G. Oxidative stress regulates the Vascular endothelial growth factor A (VEGF-A) gene in gastric carcinoma cells through Sp1- and Sp3- dependent activation of a GC-rich response element. Cramer, T., Rosewicz, S., Wiedenmann, B., and Hocker, M. Manuscript submitted . 2002.
59. Milani S, Herbst H, Schuppan D, Hahn EG, Stein H. In situ hybridization for procollagen types I, III and IV mRNA in normal and fibrotic rat liver: evidence for predominant expression in nonparenchymal liver cells. *Hepatology.* 1989;10:84-92.
60. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. *N Engl J Med.* 1991;324:1-8.
61. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K, Kamada T. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. *Cancer Res.* 1996;56:3004-3009.
62. Hagen G, Muller S, Beato M, Suske G. Cloning by recognition site screening of two novel GT box binding proteins: a family of Sp1 related genes. *Nucleic Acids Res.* 1992;20:5519-5525.
63. Li CY, Shan S, Cao Y, Dewhirst MW. Role of incipient angiogenesis in cancer metastasis. *Cancer Metastasis Rev.* 2000;19:7-11.
64. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. *J Pathol.* 1998;184:119-122.
65. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. *Breast Cancer Res Treat.* 1995;36:169-180.
66. Plate K. From angiogenesis to lymphangiogenesis. *Nat Med.* 2001;7:151-152.
67. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. *Cancer Res.* 1993;53:4727-4735.

68. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. *Nature*. 1992;359:845-848.
69. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. *Cancer Res*. 1995;55:3964-3968.
70. Reeves ME, DeMatteo RP. Genes and viruses in hepatobiliary neoplasia. *Semin Surg Oncol*. 2000;19:84-93.
71. Jonas S, Springmeier G, Tauber R, Wiedenmann B, Lobeck H, Gessner R, Kreft B, Kling N, Moelling K, Neuhaus P. p53 mutagenesis in Klatskin tumors. *Hum Pathol*. 1998;29:955-960.
72. Grande JP. Role of transforming growth factor-beta in tissue injury and repair. *Proc Soc Exp Biol Med*. 1997;214:27-40.
73. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. *N Engl J Med*. 1994;331:1286-1292.
74. Oberhammer F, Bursch W, Parzefall W, Breit P, Erber E, Stadler M, Schulte-Hermann R. Effect of transforming growth factor beta on cell death of cultured rat hepatocytes. *Cancer Res*. 1991;51:2478-2485.
75. De Bleser PJ, Niki T, Xu G, Rogiers V, Geerts A. Localization and cellular sources of activins in normal and fibrotic rat liver. *Hepatology*. 1997;26:905-912.
76. Vogelbruch M, Wellmann A, Maschek H, Schafer MK, Flemming P, Georgii A. Transforming growth factor beta 1 in human liver tumors. *Verh Dtsch Ges Pathol*. 1995;79:132-136.
77. Chen Y, Sasatomi E, Satoh T, Miyazaki K, Tokunaga O. Abnormal distribution of collagen type IV in extrahepatic bile duct carcinoma. *Pathol Int*. 2000;50:884-890.
78. Fajardo LF, Prionas SD, Kwan HH, Kowalski J, Allison AC. Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern. *Lab Invest*. 1996;74:600-608.
79. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. *Circulation*. 1994;90:649-652.
80. Milanini J, Vinals F, Pouyssegur J, Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. *J Biol Chem*. 1998;273:18165-18172.
81. Salimath B, Marme D, Finkenzeller G. Expression of the vascular endothelial growth factor gene is inhibited by p73. *Oncogene*. 2000;19:3470-3476.
82. Tu ZJ, Pan W, Gong Z, Kiang DT. Involving AP-2 transcription factor in connexin 26 up-regulation during pregnancy and lactation. *Mol Reprod Dev*. 2001;59:17-24.

83. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. *Cell*. 1998;94:585-594.
84. Labbe E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. *Mol Cell*. 1998;2:109-120.
85. Kusanagi K, Inoue H, Ishidou Y, Mishima HK, Kawabata M, Miyazono K. Characterization of a bone morphogenetic protein-responsive Smad-binding element. *Mol Biol Cell*. 2000;11:555-565.
86. Li JM, Datto MB, Shen X, Hu PP, Yu Y, Wang XF. Sp1, but not Sp3, functions to mediate promoter activation by TGF-beta through canonical Sp1 binding sites. *Nucleic Acids Res*. 1998;26:2449-2456.
87. Pardali K, Kurisaki A, Moren A, Ten Dijke P, Kardassis D, Moustakas A. Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-beta. *J Biol Chem*. 2000;275:29244-29256.
88. Feng XH, Lin X, Derynck R. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta. *EMBO J*. 2000;19:5178-5193.
89. Poncelet AC, Schnaper HW. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2(I) collagen expression in human glomerular mesangial cells. *J Biol Chem*. 2001;276:6983-6992.